EN
SINOVAC Provides Vaccines to Step Up Preventative Healthcare for Children in Turkey
Company's Overseas Delivery of Varicella Vaccine and Approval to Expand Use of CoronaVac Will Help Turkish Minors Combat Infectious Diseases
February 3, 2023, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced recent developments in Turkey that will enhance pediatric health outcomes, including the successful delivery of its varicella vaccine and expanded approval of its COVID-19 vaccine for children 3 years and above.
The delivery of SINOVAC's varicella vaccine to Turkey marks the vaccine's first international shipment, while the Turkish Medicines and Medical Devices Agency's expansion of Emergency Use Approval (EUA) for SINOVAC's COVID-19 vaccine, CoronaVac®, will allow more young groups to be protected.
SINOVAC, an international partner in Turkey's national healthcare efforts, has supplied the country with millions of doses of its vaccines and continues to support local communities in the fight against infectious diseases such as varicella and COVID-19.
SINOVAC's varicella vaccine provides great protection
SINOVAC's live attenuated varicella vaccine was prequalified by the World Health Organization (WHO) in November 2022 and is the first WHO-approved Chinese vaccine of its kind. The varicella vaccine is derived from the Oka strain and propagated using SINOVAC's proprietary Human Diploid Cell (SV-1 strain). A phase III efficacy study showed that the seroconversion rate in vaccinated children aged 1 to 12 years was 97.1%, with vaccine efficacy of 87.1% against varicella and 89.2% for breakthrough varicella. The vaccine provides 100% protection against moderate and severe cases.
Varicella vaccines has been part of Turkey's routine national childhood immunizations since the beginning of 2013, with a single dose administered to 12-month-old children. Vaccination helps prevent the development of chickenpox caused by the varicella zoster virus. The success of Turkey's childhood vaccinations has reduced the severity of the disease, the risk of transmission and use of healthcare resources, as well as the risk of shingles after infection. According to a time-trend study1, which compared the period before and after introducing the varicella vaccine into Turkey's national immunization program, the annual incidence of varicella in children aged 1 to 5 years significantly decreased from 290 per 100,000 children in 2011, to 24 per 100,000 children in 2019.
CoronaVac® protects hundreds of millions of children worldwide
In Turkey, CoronaVac® was previously validated for emergency use in individuals aged 18 and above. The expansion makes CoronaVac® the only COVID-19 vaccine to be used for individuals aged 3 and above, the youngest group approved for the vaccination, in the country.
CoronaVac® has been approved for use in children and adolescents in 16 countries, regions, and international organizations and offers protection to millions of children worldwide. The vaccine has been validated by the WHO for use in children as young as 3 under the Emergency Use Listing ("EUL") Procedure. This is also the youngest age that the WHO has validated for the EUL of COVID-19 vaccines in the world to date.
Reference:
About SINOVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Paneflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.